Endpoints News

Pfizer and Arvinas' breast cancer drug approval		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

Mon T W Th F

4 May, 2026

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us

presented by

Biocon’s Bold Integration: Unifying Biosimilars and Generics to Redefine Global Affordable Access

news

UCB bets $2B on Candid's T cell engager ambitions

FDA approves Pfizer and Arvinas' breast cancer drug despite underwhelming data

Moderna in talks with FDA over post-marketing Covid shot data, with eyes on wider access

Amgen launches late-stage obesity trial in patients who switch from rival drugs

Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research

Summit slips on ivonescimab's apparent interim miss in sign of investor frustration

Peer Review

Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit

Acelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China

May 05

11:00 am ET

The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development

in case you missed it

Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

J&J axes pair of CAR-T therapies for lymphoma, citing evolving market

FDA's oncology advisors vote against 'new paradigm' in AstraZeneca breast cancer trial

How Vaccine Skepticism Tanked a MAHA Hero's Ambitions

Keep it here at Endpoints for more earnings news. Pfizer and Novo Nordisk, who duked it out over obesity biotech Metsera, are next in line this week. And for our friends in the UK, have a great bank holiday!

Alex Hoffman

Senior Copy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com